STOCK TITAN

[6-K] MAINZ BIOMED N.V. Current Report (Foreign Issuer)

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
6-K

Mainz Biomed (MYNZ) entered an Equity Distribution Agreement with Maxim Group, permitting at-the-market sales of ordinary shares up to $10,000,000. The company disclosed that up to $2,300,000 of these shares may be sold under its effective Form F-3 shelf and a prospectus supplement dated October 3, 2025.

Sales, if any, may occur on Nasdaq or other U.S. markets, via methods permitted by law, including block trades. Mainz Biomed will pay a 3.0% sales commission to the agent. The company is not obligated to sell, and the agreement ends upon selling all offered shares or termination by either party.

Mainz Biomed (MYNZ) ha stipulato un accordo di distribuzione azionaria con Maxim Group, che consente vendite sul mercato di azioni ordinarie fino a $10,000,000. L'azienda ha comunicato che fino a $2,300,000 di queste azioni possono essere vendute nell'ambito del suo Form F-3 shelf efficace e di un supplemento al prospetto datato 3 ottobre 2025.

Le vendite, se presenti, possono avere luogo su Nasdaq o altri mercati negli Stati Uniti, tramite metodi consentiti dalla legge, inclusi block trades. Mainz Biomed pagherà all'agente una commissione di vendita del 3,0%. L'azienda non è obbligata a vendere, e l'accordo termina al completo venduto di tutte le azioni offerte o per risoluzione da parte di una delle parti.

Mainz Biomed (MYNZ) entró en un Acuerdo de Distribución de Acciones con Maxim Group, que permite ventas en el mercado de acciones ordinarias por hasta $10,000,000. La empresa informó que hasta $2,300,000 de estas acciones pueden venderse bajo su shelf de Form F-3 vigente y un suplemento de prospecto con fecha del 3 de octubre de 2025.

Las ventas, si las hay, pueden realizarse en Nasdaq u otros mercados de EE. UU., mediante métodos permitidos por la ley, incluidas operaciones a bloques. Mainz Biomed pagará al agente una comisión de ventas del 3,0%. La empresa no está obligada a vender, y el acuerdo termina cuando se venden todas las acciones ofrecidas o por terminación por cualquiera de las partes.

Mainz Biomed (MYNZ)가 Maxim Group과 주식 배분 계약을 체결하여 보통주를 최대 $10,000,000까지 시장 매매로 판매할 수 있도록 허용했습니다. 회사는 이 주식 중 최대 $2,300,000가 유효한 Form F-3 선반 및 2025년 10월 3일자 증권설명서 보충에 따라 매각될 수 있다고 공시했습니다.

판매가 있을 경우 Nasdaq 또는 미국의 다른 시장에서 법으로 허용된 방법으로, 블록 거래를 포함하여 이루어질 수 있습니다. Mainz Biomed는 중개인에게 3.0%의 판매 수수료를 지급합니다. 회사는 매도 의무가 없으며, 모든 제공 주식이 팔리거나 어느 한 당사자에 의한 해지 시에 계약이 종료됩니다.

Mainz Biomed (MYNZ) a conclu un accord de distribution d'actions avec Maxim Group, autorisant des ventes sur le marché d'actions ordinaires jusqu'à 10 000 000 $. La société a indiqué que jusqu'à 2 300 000 $ de ces actions peuvent être vendues en vertu de son Form F-3 shelf en vigueur et d'un supplément de prospectus daté du 3 octobre 2025.

Les ventes, le cas échéant, peuvent se dérouler sur Nasdaq ou d'autres marchés américains, par des méthodes autorisées par la loi, y compris les transactions en bloc. Mainz Biomed versera à l'agent une commission de vente de 3,0%. La société n'est pas obligée de vendre et l'accord prend fin lorsque toutes les actions offertes sont vendues ou par résiliation par l'une des parties.

Mainz Biomed (MYNZ) hat mit Maxim Group eine Equity Distribution Agreement abgeschlossen, das dem Marktverkauf von Stammaktien bis zu 10.000.000 $ ermöglicht. Das Unternehmen gab bekannt, dass bis zu 2.300.000 $ dieser Aktien unter seinem wirksamen Form F-3 Shelf und einem am 3. Oktober 2025 datierten Prospektzuschlag verkauft werden können.

Verkäufe, falls vorhanden, können an der Nasdaq oder an anderen US-Märkten erfolgen, mittels gesetzlich zulässiger Methoden, einschließlich Block Trades. Mainz Biomed zahlt dem Agenten eine Verkaufsprovision von 3,0%. Das Unternehmen ist nicht verpflichtet zu verkaufen, und das Abkommen endet, sobald alle angebotenen Aktien verkauft sind oder durch Kündigung einer der Parteien.

Mainz Biomed (MYNZ) دخلت في اتفاقية توزيع حقوق الملكية مع Maxim Group، تسمح ببيع الأسهم العادية في السوق حتى 10,000,000 دولار. أصدرت الشركة بياناً يفيد بأن حتى 2,300,000 دولار من هذه الأسهم قد تُباع بموجب Form F-3 shelf الساري ومُلحق نشرة الإصدار المؤرَّخ 3 أكتوبر 2025.

قد تتم المبيعات، إن وجدت، في Nasdaq أو أسواق أمريكية أخرى، عبر طرق يسمح بها القانون، بما في ذلك التداولات بالجملة. ستدفع Mainz Biomed عمولة بيع قدرها 3.0% للوكلاء. ليست الشركة ملزمة بالبيع، وينتهي الاتفاق عند بيع جميع الأسهم المعروضة أو عند إنهاء من أي طرف.

Mainz Biomed (MYNZ) 与 Maxim Group 签署了<参>股票发行分销协议,允许对普通股进行市场销售,总额最高可达 10,000,000 美元。公司披露称,在其有效的 Form F-3 shelf 及日期为 2025 年 10 月 3 日的招股说明书增补中,最多可出售其中 2,300,000 美元 的股票。

若有销售,可能在 Nasdaq 或其他美国市场进行,方式符合相关法律允许的方法,包括大宗交易。Mainz Biomed 将向代理人支付 3.0% 的销售佣金。公司并无出售义务,且当所有公开发行的股票售出或任一方终止时,协议终止。

Positive
  • None.
Negative
  • None.

Mainz Biomed (MYNZ) ha stipulato un accordo di distribuzione azionaria con Maxim Group, che consente vendite sul mercato di azioni ordinarie fino a $10,000,000. L'azienda ha comunicato che fino a $2,300,000 di queste azioni possono essere vendute nell'ambito del suo Form F-3 shelf efficace e di un supplemento al prospetto datato 3 ottobre 2025.

Le vendite, se presenti, possono avere luogo su Nasdaq o altri mercati negli Stati Uniti, tramite metodi consentiti dalla legge, inclusi block trades. Mainz Biomed pagherà all'agente una commissione di vendita del 3,0%. L'azienda non è obbligata a vendere, e l'accordo termina al completo venduto di tutte le azioni offerte o per risoluzione da parte di una delle parti.

Mainz Biomed (MYNZ) entró en un Acuerdo de Distribución de Acciones con Maxim Group, que permite ventas en el mercado de acciones ordinarias por hasta $10,000,000. La empresa informó que hasta $2,300,000 de estas acciones pueden venderse bajo su shelf de Form F-3 vigente y un suplemento de prospecto con fecha del 3 de octubre de 2025.

Las ventas, si las hay, pueden realizarse en Nasdaq u otros mercados de EE. UU., mediante métodos permitidos por la ley, incluidas operaciones a bloques. Mainz Biomed pagará al agente una comisión de ventas del 3,0%. La empresa no está obligada a vender, y el acuerdo termina cuando se venden todas las acciones ofrecidas o por terminación por cualquiera de las partes.

Mainz Biomed (MYNZ)가 Maxim Group과 주식 배분 계약을 체결하여 보통주를 최대 $10,000,000까지 시장 매매로 판매할 수 있도록 허용했습니다. 회사는 이 주식 중 최대 $2,300,000가 유효한 Form F-3 선반 및 2025년 10월 3일자 증권설명서 보충에 따라 매각될 수 있다고 공시했습니다.

판매가 있을 경우 Nasdaq 또는 미국의 다른 시장에서 법으로 허용된 방법으로, 블록 거래를 포함하여 이루어질 수 있습니다. Mainz Biomed는 중개인에게 3.0%의 판매 수수료를 지급합니다. 회사는 매도 의무가 없으며, 모든 제공 주식이 팔리거나 어느 한 당사자에 의한 해지 시에 계약이 종료됩니다.

Mainz Biomed (MYNZ) a conclu un accord de distribution d'actions avec Maxim Group, autorisant des ventes sur le marché d'actions ordinaires jusqu'à 10 000 000 $. La société a indiqué que jusqu'à 2 300 000 $ de ces actions peuvent être vendues en vertu de son Form F-3 shelf en vigueur et d'un supplément de prospectus daté du 3 octobre 2025.

Les ventes, le cas échéant, peuvent se dérouler sur Nasdaq ou d'autres marchés américains, par des méthodes autorisées par la loi, y compris les transactions en bloc. Mainz Biomed versera à l'agent une commission de vente de 3,0%. La société n'est pas obligée de vendre et l'accord prend fin lorsque toutes les actions offertes sont vendues ou par résiliation par l'une des parties.

Mainz Biomed (MYNZ) hat mit Maxim Group eine Equity Distribution Agreement abgeschlossen, das dem Marktverkauf von Stammaktien bis zu 10.000.000 $ ermöglicht. Das Unternehmen gab bekannt, dass bis zu 2.300.000 $ dieser Aktien unter seinem wirksamen Form F-3 Shelf und einem am 3. Oktober 2025 datierten Prospektzuschlag verkauft werden können.

Verkäufe, falls vorhanden, können an der Nasdaq oder an anderen US-Märkten erfolgen, mittels gesetzlich zulässiger Methoden, einschließlich Block Trades. Mainz Biomed zahlt dem Agenten eine Verkaufsprovision von 3,0%. Das Unternehmen ist nicht verpflichtet zu verkaufen, und das Abkommen endet, sobald alle angebotenen Aktien verkauft sind oder durch Kündigung einer der Parteien.

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 

UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of October 2025

 

Commission File No. 001-41010

 

MAINZ BIOMED N.V.

(Translation of registrant’s name into English)

 

Robert Koch Strasse 50
55129 Mainz
Germany

(Address of principal executive office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F

 

Form 20-F ☒     Form 40-F 

 

 

  

 

 

 

Entry into Material Agreements

 

On October 3, 2025, we entered into an Equity Distribution Agreement (the “Sales Agreement”) with Maxim Group LLC (the “Sales Agent”), pursuant to which we may elect to sell, from time to time through the Sales Agent, our ordinary shares, nominal value €0.40 per share (the “Ordinary Shares”), having an aggregate offering amount of up to $10,000,000 (collectively, the “Offered Shares”).

 

Any potential sale of up to $2,300,000 of the Offered Shares will be made pursuant to our effective shelf registration statement on Form F-3, including the prospectus contained therein (File No. 333-269091) filed with the U.S. Securities and Exchange Commission (the “SEC”) on December 30, 2022 and declared effective on January 6, 2023, as supplemented by a prospectus supplement (the “Prospectus Supplement”), dated October 3, 2025 and filed with the SEC pursuant to Rule 424(b) under the Securities Act of 1933, as amended (the “Securities Act”).

 

If we elect from time to time to sell Ordinary Shares under the Prospectus Supplement, such sales may be made in transactions that are deemed to be “at-the-market” offerings as defined in Rule 415 under the Securities Act, including sales made directly on or through the Nasdaq Capital Market, the existing trading market for the Ordinary Shares, or any other existing trading market in the United States for the Ordinary Shares, sales made to or through a market maker other than on an exchange or otherwise, directly to a Sales Agent as principal, in negotiated transactions, or in any other method permitted by law, which may include block trades. The Sales Agent has agreed to use commercially reasonable efforts consistent with their normal trading and sales practices to sell the Offered Shares pursuant to the Sales Agreement from time to time, based upon instructions from us, including any price or size limits or other customary parameters or conditions we may impose.

 

We are not obligated to sell any Offered Shares under the Sales Agreement. The Sales Agreement will terminate upon the earliest of (a) the sale of all of the Offered Shares and (b) the termination of the Sales Agreement by the Sales Agent or us, as permitted therein.

 

We have agreed to pay the Sales Agent a commission of 3.0% of the gross sales price from each sale of Offered Shares pursuant to the Sales Agreement and have agreed to customary indemnification and contribution rights in favor of the Sales Agent. Additionally, we have agreed to reimburse the Sales Agent for certain specified expenses in connection with entering into the Sales Agreement and ongoing sales thereunder. The Sales Agreement contains customary representations and warranties and conditions to the sale of the Offered Shares thereunder.

 

The foregoing description of the Sales Agreement is not complete and is qualified in its entirety by reference to the full text of such agreement, a copy of which is filed herewith as Exhibit 10.1 to this Report on Form 6-K and is incorporated herein by reference.

 

This Report on Form 6-K shall not constitute an offer to sell or the solicitation of an offer to buy the Offered Shares or any other securities, nor shall there be any offer, solicitation, or sale of securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.

 

Exhibit Index

 

Exhibit No.   Description
     
5.1   Opinion of CMS Derks Star Busmann N.V. regarding the validity of the securities being registered
     
10.1   Sales Agreement, dated October 3, 2025, by and among Mainz Biomed N.V. and Maxim Group LLC
     
23.1   Consent of CMS Derks Star Busmann N.V. (included in Exhibit 5.1)

 

The information contained in this Report on Form 6-K is hereby incorporated by reference into our Registration Statement on Form F-3 (File No. 333-269091) and into the base prospectus and any prospectus supplement outstanding under the foregoing registration statement.

 

1

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: October 3, 2025 By: /s/ William J. Caragol
    Chief Financial Officer

 

2

FAQ

What did Mainz Biomed (MYNZ) announce in this 6-K?

The company entered an Equity Distribution Agreement enabling at-the-market sales of ordinary shares up to $10,000,000 through Maxim Group.

How much can MYNZ sell under the current prospectus supplement?

The filing states that up to $2,300,000 of shares may be sold under the effective Form F-3 and the October 3, 2025 prospectus supplement.

What commission will MYNZ pay on ATM sales?

Mainz Biomed agreed to pay the sales agent a 3.0% commission on the gross sales price of shares sold.

Is Mainz Biomed obligated to sell shares under the agreement?

No. The company is not obligated to sell any shares under the Equity Distribution Agreement.

Where can ATM sales of MYNZ shares occur?

Sales may be made on or through the Nasdaq Capital Market or other existing U.S. trading markets, including negotiated transactions and block trades.

When does the Equity Distribution Agreement end?

It terminates upon the earlier of selling all offered shares or termination by either Mainz Biomed or the sales agent.

Which registration statement covers the sales?

The sales are covered by Form F-3 (File No. 333-269091) and the prospectus supplement dated October 3, 2025.
Mainz Biomed NV

NASDAQ:MYNZ

MYNZ Rankings

MYNZ Latest News

MYNZ Latest SEC Filings

MYNZ Stock Data

7.63M
5.34M
1.63%
8.43%
2.35%
Diagnostics & Research
Healthcare
Link
Germany
Mainz